Protagenic Therapeutics, Inc.\new Book Value Per Share Growth & History (PTIX)
Protagenic Therapeutics, Inc.\new's book value per share was $1.45 for fiscal 2026.
View full Protagenic Therapeutics, Inc.\new company overviewProtagenic Therapeutics, Inc.\new annual book value per share history
| Fiscal year | Period ended | Book value per share | Change | Growth |
|---|---|---|---|---|
| 2026 | 2026-03-31 | $1.45 | $2.30 | — |
| 2025 | 2025-03-31 | -$0.85 | — | — |
| 2024 | 2024-12-31 | -$6.41 | -$17.99 | — |
| 2023 | 2023-12-31 | $11.58 | -$10.83 | −48.33% |
| 2022 | 2022-12-31 | $22.41 | -$9.94 | −30.73% |
| 2021 | 2021-12-31 | $32.35 | $38.57 | — |
| 2020 | 2020-12-31 | -$6.21 | -$2.75 | — |
| 2019 | 2019-12-31 | -$3.46 | -$2.31 | — |
| 2018 | 2018-12-31 | -$1.15 | -$7.81 | — |
| 2017 | 2017-12-31 | $6.65 | -$6.87 | −50.80% |
| 2016 | 2016-12-31 | $13.52 | $19.22 | — |
| 2015 · Dec 31 | 2015-12-31 | -$5.69 | — | — |
| 2015 · Jun 30 | 2015-06-30 | -$0.07 | -$0.07 | — |
| 2014 | 2014-06-30 | -$0.00 | — | — |
Protagenic Therapeutics, Inc.\new quarterly book value per share
| Fiscal quarter | Period ended | Book value per share | Change | YoY change |
|---|---|---|---|---|
| Q1 2027 | 2026-06-30 | $0.95 | $3.10 | — |
| Q4 2026 | 2026-03-31 | $1.45 | $2.30 | — |
| Q3 2026 | 2025-12-31 | -$1.24 | $5.18 | — |
| Q2 2026 | 2025-09-30 | -$2.43 | $4.77 | — |
| Q1 2026 | 2025-06-30 | -$2.15 | $3.34 | — |
| Q4 2025 | 2025-03-31 | -$0.85 | $4.79 | — |
| Q4 2024 | 2024-12-31 | -$6.41 | -$17.99 | — |
| Q3 2024 | 2024-09-30 | -$7.20 | -$20.62 | — |
| Q2 2024 | 2024-06-30 | -$5.49 | -$22.99 | — |
| Q1 2024 | 2024-03-31 | -$5.65 | -$26.38 | — |
| Q4 2023 | 2023-12-31 | $11.58 | -$10.83 | −48.33% |
| Q3 2023 | 2023-09-30 | $13.42 | -$10.49 | −43.87% |
| Q2 2023 | 2023-06-30 | $17.50 | -$9.25 | −34.59% |
| Q1 2023 | 2023-03-31 | $20.73 | -$7.57 | −26.74% |
| Q4 2022 | 2022-12-31 | $22.41 | -$9.94 | −30.73% |
| Q3 2022 | 2022-09-30 | $23.92 | $58.17 | — |
| Q2 2022 | 2022-06-30 | $26.75 | -$10.43 | −28.04% |
| Q1 2022 | 2022-03-31 | $28.30 | $38.77 | — |
| Q4 2021 | 2021-12-31 | $32.35 | $38.57 | — |
| Q3 2021 | 2021-09-30 | -$34.25 | -$28.73 | — |
| Q2 2021 | 2021-06-30 | $37.18 | $40.78 | — |
| Q1 2021 | 2021-03-31 | -$10.46 | -$7.27 | — |
| Q4 2020 | 2020-12-31 | -$6.21 | -$2.75 | — |
| Q3 2020 | 2020-09-30 | -$5.52 | -$3.53 | — |
| Q2 2020 | 2020-06-30 | -$3.60 | -$1.53 | — |
| Q1 2020 | 2020-03-31 | -$3.20 | -$1.22 | — |
| Q4 2019 | 2019-12-31 | -$3.46 | -$2.31 | — |
| Q3 2019 | 2019-09-30 | -$1.99 | -$3.75 | — |
| Q2 2019 | 2019-06-30 | -$2.07 | -$5.13 | — |
| Q1 2019 | 2019-03-31 | -$1.97 | -$7.24 | — |
| Q4 2018 | 2018-12-31 | -$1.15 | -$7.81 | — |
| Q3 2018 | 2018-09-30 | $1.76 | -$7.42 | −80.80% |
| Q2 2018 | 2018-06-30 | $3.06 | -$7.19 | −70.17% |
| Q1 2018 | 2018-03-31 | $5.27 | -$6.62 | −55.69% |
| Q4 2017 | 2017-12-31 | $6.65 | -$6.87 | −50.80% |
| Q3 2017 | 2017-09-30 | $9.18 | -$10.62 | −53.64% |
| Q2 2017 | 2017-06-30 | $10.24 | -$2,062.83 | −99.51% |
| Q1 2017 | 2017-03-31 | $11.88 | $11.46 | +2714.04% |
| Q4 2016 | 2016-12-31 | $13.52 | $19.22 | — |
| Q3 2016 | 2016-09-30 | $19.81 | $19.90 | — |
| Q2 2016 | 2016-06-30 | $2,073.07 | $2,073.14 | — |
| Q1 2016 · Mar 31 | 2016-03-31 | $0.42 | $0.48 | — |
| Q4 2015 · Dec 31 | 2015-12-31 | -$5.69 | -$5.65 | — |
| Q1 2016 · Sep 30 | 2015-09-30 | -$0.09 | -$0.07 | — |
| Q4 2015 · Jun 30 | 2015-06-30 | -$0.07 | -$0.07 | — |
| Q3 2015 | 2015-03-31 | -$0.05 | — | — |
| Q2 2015 | 2014-12-31 | -$0.04 | — | — |
| Q1 2015 | 2014-09-30 | -$0.02 | — | — |
| Q4 2014 | 2014-06-30 | -$0.00 | — | — |
| As of Sep 30, 2011 | 2011-09-30 | -$49.91 | — | — |
| As of Jun 30, 2011 | 2011-06-30 | -$9.86 | — | — |
Protagenic Therapeutics, Inc.\new book value per share trends
Between the periods ended 2014-06-30 and 2026-03-31, Protagenic Therapeutics, Inc.\new's book value per share increased from -$0.00 to $1.45, a change of $1.45. The latest reported quarter, Q1 2027, shows $0.95.
What book value per share means
Book value per share estimates the common shareholders’ accounting equity represented by each share. It can help compare a company’s balance-sheet value over time, although market value can differ substantially from book value.
How book value per share is calculated
TickerStat calculates book value per share as SEC-reported common shareholders’ equity divided by reported period-end common shares. Preferred equity is subtracted when separately reported, and basic weighted-average shares are used only when period-end shares are unavailable. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Protagenic Therapeutics, Inc.\new source filings ↗